An investigation of pharmacovigilance and reporting of adverse drug reactions in hospitals: a cross-sectional study in China

References

• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998;279(15):1200–1205.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The importance of pharmacovigilance. Vol. 9241590157. World Health Organization; 2002.
   Google Scholar
• Uppsala Monitoring Centre (UMC). WHO Programme members. [cited 2020 Nov 14]. https://www.who-umc.org/global-pharmacovigilance/who-programme-for-international-drug-monitoring/
   Google Scholar
• Hussain R, Hassali MA. Medicines safety in the globalized context. Global pharmaceutical policy. Singapore: Palgrave Macmillan; 2020. p. 1–28.
   Google Scholar
• Li R, Curtis K, Zaidi STR, et al. Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions. Expert Opin Drug Saf. 2021;1–8. DOI:https://doi.org/10.1080/14740338.2021.1938539
   Web of Science ®Google Scholar
• Niu R, Xiang Y, Wu T, et al. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance Centre in Western China. Expert Opin Drug Saf. 2019;18(1):51–58.
   PubMed Web of Science ®Google Scholar
• Hailu AD, Mohammed SA. Adverse drug reaction reporting in Ethiopia: systematic review. Biomed Res Int. 2020;2020:8569314.
   PubMed Web of Science ®Google Scholar
• Adisa R, Omitogun TI. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. BMC Health Serv Res. 2019;19(1):926.
   PubMed Web of Science ®Google Scholar
• Valinciute-Jankauskiene A, Kubiliene L. Adverse drug reaction reporting by patients in 12 European countries. Int J Environ Res Public Health. 2021;18(4):1507.
   PubMed Web of Science ®Google Scholar
• Gildeeva G, Belostotsky A. Pharmacovigilance in Russia: current state of affairs, challenges, and prospects. Curr Med Res Opin. 2017;33(12):2161–2166.
   PubMed Web of Science ®Google Scholar
• Montané E, Arellano AL, Sanz Y, et al. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol. 2018;84(3):542–552.
   PubMed Web of Science ®Google Scholar
• Kovačević M, Vezmar Kovačević S, Radovanović S, et al. Adverse drug reactions caused by drug-drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. Curr Med Res Opin. 2019;35(11):1873–1883.
   PubMed Web of Science ®Google Scholar
• Ribeiro-Vaz I, Silva AM, Costa Santos C, et al. How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis. BMC Med Inform Decis Mak. 2016;16:27.
   PubMed Web of Science ®Google Scholar
• Handbook of resolutions and decisions of the World Health Assembly and the Executive Board. Vol. 11948-1972. Geneva: World Health Organization; 1973.
   Google Scholar
• Administration. TIT. Top markets report pharmaceuticals country case study. https://www.trade.gov/topmarkets/pdf/PharmaceuticalsChina.pdf. [cited 2020 Nov 21; 2016].
   Google Scholar
• Zhou H-H, Zeng F-D, Tang J. Pharmacovigilance in China. In: Mann’s pharmacovigilance. New York: Wiley; 2014. p. 263–265.
   Google Scholar
• Administration CFaD. Measures for the reporting and monitoring of adverse drug reaction (for trial implementation). [cited 2020 Nov 19; 1999]. http://wwwsfdagovcn/WS01/CL0058/9305html.
   Google Scholar
• Xie Y, Tian F. [A discussion of key issues on postmarketing reevaluation of Chinese medicine]. Zhongguo Zhong Yao Za Zhi. 2010;35(11):1494–1497.
   PubMedGoogle Scholar
• Zhao Y, Wang T, Li G, et al. Pharmacovigilance in China: development and challenges. Int J Clin Pharm. 2018;40(4):823–831.
   PubMed Web of Science ®Google Scholar
• Li L, Yin J. Drug safety evaluation in China. Curr Allergy Asthma Rep. 2019;19(9):39.
   PubMed Web of Science ®Google Scholar
• Administration CFaD. Annual ADR reporton national ADR monitoring. Available from: http://www.sda.gov.cn/WS01/CL0844/172167.html. 2018.
   Google Scholar
• Zhang X, Niu R, Feng B, et al. Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study. Expert Opin Drug Saf. 2019;18(1):59–68.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang Y, Wang N, et al. Knowledge, attitude, and practice regarding pharmacovigilance among the general public in Western China: a cross-sectional study. Curr Med Res Opin. 2021;37(1):101–108.
   PubMed Web of Science ®Google Scholar
• Al-Mutairi A, AlFayyad I, Altannir Y, et al. Medication safety knowledge, attitude, and practice among hospital pharmacists in tertiary care hospitals in Saudi Arabia: a multi-center study. Arch Public Health. 2021;79(1):130.
   PubMed Web of Science ®Google Scholar
• Gahr M, Connemann B, Zeiss R, et al. Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey. Expert Opin Drug Saf. 2021;9:1–7.
   Web of Science ®Google Scholar
• Fang H, Lin X, Zhang J, et al. Multifaceted interventions for improving spontaneous reporting of adverse drug reactions in a general hospital in China. BMC Pharmacol Toxicol. 2017;18(1):49.
   PubMed Web of Science ®Google Scholar
• Chang F, Xi Y, Zhao J, et al. A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. J Eval Clin Pract. 2017;23(6):1316–1321.
   PubMed Web of Science ®Google Scholar
• Agoro OO, Kibira SW, Freeman JV, et al. Barriers to the success of an electronic pharmacovigilance reporting system in Kenya: an evaluation three years post implementation. J Am Med Inform Assoc. 2018;25(6):627–634.
   PubMed Web of Science ®Google Scholar
• Chen C, Jia W, Guo D, et al. Development of a computer-assisted adverse drug events alarm and assessment system for hospital inpatients in China. Ther Innov Regul Sci. 2020;54(1):32–41.
   PubMed Web of Science ®Google Scholar
• Wang M, Ye X, Ruan Y, et al. Detection of cluster adverse drug events in the spontaneous reporting system of China using a disproportionality filter algorithm. J Clin Pharm Ther. 2019;44(6):952–957.
   PubMed Web of Science ®Google Scholar
• Nadew SS, Beyene KG, Beza SW. Adverse drug reaction reporting practice and associated factors among medical doctors in government hospitals in Addis Ababa, Ethiopia. PLoS One. 2020;15(1):e0227712.
   PubMed Web of Science ®Google Scholar
• Fornasier G, Taborelli M, Francescon S, et al. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance. Int J Clin Pharm. 2018;40(4):795–802.
   PubMed Web of Science ®Google Scholar
• Aldryhim AY, Alomair A, Alqhtani M, et al. Factors that facilitate reporting of adverse drug reactions by pharmacists in Saudi Arabia. Expert Opin Drug Saf. 2019;18(8):745–752.
   PubMed Web of Science ®Google Scholar
• Administration. NMP. The annual report on national adverse drug reaction monitoring in 2019. [cited 2020 November 19]. http://medchinacomcn/content/pid/170952/tid/1022.
   Google Scholar
• Güner MD, Ekmekci PE. Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. J Drug Assess. 2019;8(1):13–20.
   PubMed Web of Science ®Google Scholar
• Ali MD, Hassan YA, Ahmad A, et al. Knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process among health care providers in Dammam, Saudi Arabia. Curr Drug Saf. 2018;13(1):21–25.
   PubMed Web of Science ®Google Scholar
• De Meestere D, Saevels J. Belgian community pharmacists’ pharmacovigilance perspective and practice. Res Social Adm Pharm. 2019;15(12):1446–1452.
   PubMed Web of Science ®Google Scholar
• Hajj A, , Hallit S, Ramia E, et al. Medication safety knowledge, attitudes and practices among community pharmacists in Lebanon. Curr Med Res Opin. 2018;34(1):149–156.
   PubMed Web of Science ®Google Scholar
• Terblanche A, Meyer JC, Godman B, et al. Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng province of South Africa. Hosp Pract. 2018;46(4):221–228.
   PubMedGoogle Scholar
• Administration. NMP. Pharmacovigilance quality management practice. [cited 2021 Jul 25]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20210513151827179.html. 2021.
   Google Scholar
• Yu YM, Lee E. Enhanced knowledge of spontaneous reporting with structured educational programs in Korean community pharmacists: a cross-sectional study. BMC Med Educ. 2017;17(1):95.
   PubMed Web of Science ®Google Scholar
• Irujo M, Beitia G, Bes-Rastrollo M, et al. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf. 2007;30(11):1073–1082.
   PubMed Web of Science ®Google Scholar
• Pimpalkhute SA, Jaiswal KM, Sontakke SD, et al. Evaluation of awareness about pharmacovigilance and adverse drug reaction monitoring in resident doctors of a tertiary care teaching hospital. Indian J Med Sci. 2012;66(3–4):55–61.
   PubMedGoogle Scholar
• Hardeep , Bajaj JK, Rakesh K. A survey on the knowledge, attitude and the practice of pharmacovigilance among the health care professionals in a teaching hospital in Northern India. J Clin Diagn Res. 2013;7(1):97–99.
   PubMedGoogle Scholar
• Upadhyaya HB, Vora MB, Nagar JG, et al. Knowledge, attitude and practices toward pharmacovigilance and adverse drug reactions in postgraduate students of Tertiary Care Hospital in Gujarat. J Adv Pharm Technol Res. 2015;6(1):29–34.
   PubMed Web of Science ®Google Scholar
• Alshammari TM, Alamri KK, Ghawa YA, et al. Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in Saudi Arabia. Int J Clin Pharm. 2015;37(6):1104–1110.
   PubMed Web of Science ®Google Scholar
• Hitesh Mishra VK. Pharmacovigilance: current scenario in a tertiary care teaching medical college in North India. J Pharmacovigilance. 2013;01(02):108.
   Google Scholar
• Leone R, Moretti U, D’Incau P, et al. Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study. Drug Saf. 2013;36(4):267–276.
   PubMed Web of Science ®Google Scholar
• Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234, iii–iv.
   PubMed Web of Science ®Google Scholar
• McLernon DJ, Bond CM, Hannaford PC, et al. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf. 2010;33(9):775–788.
   PubMed Web of Science ®Google Scholar
• Netherlands Pharmacovigilance centrelareb[EB/OL] [2019-05-27]. https://www.lareb.nl/en.
   Google Scholar
• Yu YM, Kim S, Choi KH, et al. Impact of knowledge, attitude and preceptor behaviour in pharmacovigilance education. Basic Clin Pharmacol Toxicol. 2019;124(5):591–599.
   PubMed Web of Science ®Google Scholar
• Prakasam A, Nidamanuri A, Kumar S. Knowledge, perception and practice of pharmacovigilance among community pharmacists in South India. Pharm Pract (Granada). 2012;10(4):222–226.
   PubMedGoogle Scholar
• Salcedo-Diego I, Ruiz-Antorán B, Payares-Herrera C, et al. Nurses competence in the reporting of medication-related incidents: an intervention study. Nurs Open. 2021. DOI:https://doi.org/10.1002/nop2.988
   Web of Science ®Google Scholar